In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...
The Independent on MSN10d
What are the symptoms of prostate cancer and how common is it?What are the symptoms of prostate cancer and how common is it? - Formula One team owner Eddie Jordan has died from the ...
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...
11, 2025 — Researchers have discovered a new mechanism that is used by a male sex hormone ... Radiation Therapy Reduces Long-Term Side Effects for Patients With Prostate Cancer Nov. 13, 2024 ...
Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and ...
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 ...
Researchers evaluated links between lifestyle and dietary index scores and risk of death in a prospective, multiethnic cohort of men diagnosed with non-metastatic prostate cancer.
“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback